PRESERVE-003: Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
- Title
- Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
- Principal Investigator
- Almubarak, Mohammed
- Phase
- III
- Age Group
- Adult
- Applicable Disease Sites
- Lung Cancer
- Participating Institutions
- Mary Babb Randolph Cancer Center
- Contacts
- Rachel Harper
- Clinical Research Specialist
- Phone: +1 304-293-6066
- Email: rachel.harper@hsc.wvu.edu